Clinical Review on the Utility of Fecal Microbiota Transplantation in Immunocompromised Patients

被引：6

作者：

Abu-Sbeih H. ^{[1
]}

Ali F.S. ^{[2
]}

Wang Y. ^{[1
]}

机构：

[1] Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1466, Houston, 77030, TX

[2] Department of Internal Medicine, Presence Saint Joseph Hospital, Chicago, IL

来源：

Current Gastroenterology Reports | 2019年 / 21卷 / 3期

关键词：

Adverse events; Aspiration; Fecal microbiota transplantation; Hematopoietic stem cell transplant; Immunosuppression; Infection; Solid organ transplant;

D O I：

10.1007/s11894-019-0677-6

中图分类号：

学科分类号：

摘要：

Abstract: Fecal microbiota transplantation (FMT) represents a promising management modality for Clostridium difficile infection (CDI). In immunocompromised patients, FMT is utilized for CDI as well as emerging non-CDI indications such as inflammatory bowel disease and graft versus host disease. Purpose of Review: This review aims to shed light on the safety and efficacy of FMT in immunocompromised patients, including patients suffering for human immunodeficiency virus infection, solid organ and hematopoietic stem cell transplant recipients, cancer patients, and patients on immunosuppressive therapies. Recent Findings: Though the body of evidence concerning the use of FMT in immunocompromised is growing, no clinical trials exist to date. Summary: Present literature weighs in favor of FMT in immunocompromised patients, with an acceptable adverse effect profile and minimal risk of infectious adverse events. Further large scale studies and randomized controlled trials to validate the utility of FMT in immunocompromised individuals will be a welcomed endeavor. © 2019, Springer Science+Business Media, LLC, part of Springer Nature.

引用

共 89 条

[1]

Di Bella S., Gouliouris T., Petrosillo N., Fecal microbiota transplantation (FMT) for Clostridium difficile infection: Focus on immunocompromised patients, J Infect Chemother, 21, pp. 230-237, (2015)

[2]

Bibbo S., Lopetuso L., Ianiro G., TDR-J of immunology, 2014 undefined, Role of Microbiota and Innate Immunity in Recurrent Clostridium Difficile Infection

[3]

Johnson S., Recurrent Clostridium difficile infection: Causality and therapeutic approaches, International Journal of Antimicrobial Agents, 33, pp. S33-S36, (2009)

[4]

Zhang S., Palazuelos-Munoz S., Balsells E.M., Nair H., Chit A., Kyaw M.H., Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study, BMC Infect Dis, 16, 1, (2016)

[5]

Brain D., Yakob L., Barnett A., Riley T., Clements A., Halton K., Et al., Economic evaluation of interventions designed to reduce Clostridium difficile infection, Plos One, 13, 1, (2018)

[6]

McDonald L.C., Gerding D.N., Johnson S., Bakken J.S., Carroll K.C., Coffin S.E., Et al., Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA), Clin Infect Dis [Internet], 66, 7, pp. e1-48, (2018)

[7]

Cornely O.A., Crook D.W., Esposito R., Poirier A., Somero M.S., Weiss K., Et al., Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial, Lancet Infect Dis, 12, 4, pp. 281-289, (2012)

[8]

Louie T.J., Miller M.A., Mullane K.M., Weiss K., Lentnek A., Golan Y., Et al., Fidaxomicin versus vancomycin for Clostridium difficile infection, N Engl J Med, 364, 5, pp. 422-431, (2011)

[9]

McPherson S., Rees C.J., Ellis R., Soo S., Panter S.J., Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea, Dis Colon Rectum, 49, 5, pp. 640-645, (2006)

[10]

Abougergi M.S., Broor A., Cui W., Jaar B.G., Cui W., Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: An observational study and review of the literature, J Hosp Med [Internet], 5, 1, pp. E1-E9, (2010)

← 1 2 3 4 5 6 7 8 9 →